Multivariate analysis for OS and CIR (censored for SCT)
| Covariate . | OS . | CIR . | ||
|---|---|---|---|---|
| HR (95% confidence interval) . | P value . | HR (95% confidence interval) . | P value . | |
| Model for all patients | ||||
| Age, continuous, y | 1.02 (1.00-1.03) | .025 | 0.99 (0.97-1.01) | .204 |
| Treatment cohort | ||||
| IA | Reference | Reference | ||
| LOW + VEN | 1.06 (0.70-1.61) | .786 | 0.90 (0.57-1.43) | .668 |
| Best response | ||||
| CR | Reference | Reference | ||
| CRi | 1.50 (1.03-2.17) | .033 | 1.97 (1.32-2.95) | .001 |
| MLFS | 2.66 (1.59-4.46) | <.001 | 1.84 (0.79-4.26) | .156 |
| MRD status | ||||
| Negative | Reference | Reference | ||
| Positive | 1.53 (1.13-2.08) | .006 | 1.69 (1.23-2.34) | .001 |
| ELN 2017 risk | ||||
| Favorable | Reference | Reference | ||
| Intermediate | 1.34 (0.89-2.02) | .163 | 1.92 (1.25-2.94) | .003 |
| Adverse | 1.96 (1.32-2.92) | .001 | 2.75 (1.78-4.24) | < .001 |
| Model for patients ≥60 y | ||||
| Age, continuous, y | 1.01 (0.98-1.04) | .435 | 0.99 (0.95-1.03) | .551 |
| Treatment cohort | ||||
| IA | Reference | Reference | ||
| LOW + VEN | 1.33 (0.73-2.44) | .350 | 1.30 (0.65-2.59) | .460 |
| Best response | ||||
| CR | Reference | Reference | ||
| CRi | 1.50 (0.93-2.43) | .094 | 1.96 (1.19-3.24) | .009 |
| MLFS | 4.08 (2.14-7.75) | <.001 | 1.36 (0.48-3.81) | .560 |
| MRD status | ||||
| Negative | Reference | Reference | ||
| Positive | 1.43 (0.95-2.14) | .086 | 1.73 (1.09-2.75) | .020 |
| ELN 2017 risk | ||||
| Favorable | Reference | Reference | ||
| Intermediate | 1.43 (0.78-2.63) | .248 | 2.20 (1.08-4.50) | .030 |
| Adverse | 1.88 (1.12-3.14) | .016 | 2.66 (1.43-4.96) | .002 |
| Covariate . | OS . | CIR . | ||
|---|---|---|---|---|
| HR (95% confidence interval) . | P value . | HR (95% confidence interval) . | P value . | |
| Model for all patients | ||||
| Age, continuous, y | 1.02 (1.00-1.03) | .025 | 0.99 (0.97-1.01) | .204 |
| Treatment cohort | ||||
| IA | Reference | Reference | ||
| LOW + VEN | 1.06 (0.70-1.61) | .786 | 0.90 (0.57-1.43) | .668 |
| Best response | ||||
| CR | Reference | Reference | ||
| CRi | 1.50 (1.03-2.17) | .033 | 1.97 (1.32-2.95) | .001 |
| MLFS | 2.66 (1.59-4.46) | <.001 | 1.84 (0.79-4.26) | .156 |
| MRD status | ||||
| Negative | Reference | Reference | ||
| Positive | 1.53 (1.13-2.08) | .006 | 1.69 (1.23-2.34) | .001 |
| ELN 2017 risk | ||||
| Favorable | Reference | Reference | ||
| Intermediate | 1.34 (0.89-2.02) | .163 | 1.92 (1.25-2.94) | .003 |
| Adverse | 1.96 (1.32-2.92) | .001 | 2.75 (1.78-4.24) | < .001 |
| Model for patients ≥60 y | ||||
| Age, continuous, y | 1.01 (0.98-1.04) | .435 | 0.99 (0.95-1.03) | .551 |
| Treatment cohort | ||||
| IA | Reference | Reference | ||
| LOW + VEN | 1.33 (0.73-2.44) | .350 | 1.30 (0.65-2.59) | .460 |
| Best response | ||||
| CR | Reference | Reference | ||
| CRi | 1.50 (0.93-2.43) | .094 | 1.96 (1.19-3.24) | .009 |
| MLFS | 4.08 (2.14-7.75) | <.001 | 1.36 (0.48-3.81) | .560 |
| MRD status | ||||
| Negative | Reference | Reference | ||
| Positive | 1.43 (0.95-2.14) | .086 | 1.73 (1.09-2.75) | .020 |
| ELN 2017 risk | ||||
| Favorable | Reference | Reference | ||
| Intermediate | 1.43 (0.78-2.63) | .248 | 2.20 (1.08-4.50) | .030 |
| Adverse | 1.88 (1.12-3.14) | .016 | 2.66 (1.43-4.96) | .002 |